Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

OR52D1 Inhibitors

OR52D1 inhibitors are a class of chemical compounds designed to selectively target and modulate the activity of the OR52D1 receptor, which is part of the olfactory receptor family within the G-protein-coupled receptor (GPCR) superfamily. While olfactory receptors like OR52D1 are traditionally associated with the detection of odorants in the nasal epithelium, these receptors are also expressed in various non-olfactory tissues, indicating potential roles beyond smell perception. OR52D1 inhibitors function by binding to the receptor, thereby blocking or altering its interaction with natural ligands. This inhibition can lead to changes in the signaling pathways controlled by OR52D1, which may influence a range of physiological processes. The study of these inhibitors provides valuable insights into the broader biological functions of OR52D1, particularly in non-olfactory tissues where its roles are not fully understood. Chemically, OR52D1 inhibitors can be diverse in structure and mechanism of action. Some inhibitors are designed to directly compete with endogenous ligands by binding to the receptor's active site, thereby preventing the natural ligand from initiating a signaling response. Others may act as allosteric inhibitors, binding to different sites on the receptor and inducing conformational changes that reduce its activity or alter its signaling behavior. The design and optimization of OR52D1 inhibitors typically involve detailed structural studies of the receptor, utilizing techniques such as X-ray crystallography, cryo-electron microscopy, and molecular modeling. These approaches help identify critical binding sites and guide the development of inhibitors that are both potent and selective. Researchers aim to create inhibitors that specifically target OR52D1 without affecting other GPCRs or unrelated proteins, ensuring precise modulation of the receptor's activity. By studying OR52D1 inhibitors, scientists can explore the functional roles of this receptor in various biological systems, gaining a deeper understanding of how OR52D1 contributes to different cellular processes.

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$152.00
$479.00
$632.00
$1223.00
$2132.00
33
(3)

Trichostatin A may downregulate OR52D1 by enhancing histone acetylation, which could disrupt the specific transcriptional activators from initiating the gene's transcription.

5-Azacytidine

320-67-2sc-221003
500 mg
$280.00
4
(1)

By inducing DNA demethylation, 5-Azacytidine could decrease OR52D1 transcription by altering the binding affinity of DNA-binding proteins to the gene's promoter, thereby reducing the initiation of transcription.

Mithramycin A

18378-89-7sc-200909
1 mg
$55.00
6
(1)

Mithramycin A may hinder the expression of OR52D1 by binding to its promoter DNA sequences, obstructing the association of essential transcriptional machinery with the gene, thereby decreasing its transcriptional activity.

Actinomycin D

50-76-0sc-200906
sc-200906A
sc-200906B
sc-200906C
sc-200906D
5 mg
25 mg
100 mg
1 g
10 g
$74.00
$243.00
$731.00
$2572.00
$21848.00
53
(3)

This compound could inhibit the transcription of OR52D1 by intercalating between DNA base pairs, preventing RNA polymerase from advancing along the DNA template and effectively halting the synthesis of OR52D1 mRNA.

Rifampicin

13292-46-1sc-200910
sc-200910A
sc-200910B
sc-200910C
1 g
5 g
100 g
250 g
$97.00
$328.00
$676.00
$1467.00
6
(1)

Rifampicin might repress OR52D1 expression by activating specific nuclear receptors that, upon activation, repress the transcription of certain genes, including OR52D1, by recruiting corepressor complexes to the promoter.

Chloroquine

54-05-7sc-507304
250 mg
$69.00
2
(0)

Chloroquine could decrease the stability of OR52D1 mRNA by disrupting intracellular trafficking and lysosomal degradation pathways, potentially leading to a reduction in the half-life of the OR52D1 mRNA transcript.

Sodium Butyrate

156-54-7sc-202341
sc-202341B
sc-202341A
sc-202341C
250 mg
5 g
25 g
500 g
$31.00
$47.00
$84.00
$222.00
19
(3)

Sodium Butyrate may lead to the downregulation of OR52D1 by inhibiting histone deacetylases, which changes the chromatin landscape surrounding the OR52D1 gene to a state less conducive to transcriptional activity.

Puromycin

53-79-2sc-205821
sc-205821A
10 mg
25 mg
$166.00
$322.00
436
(1)

Puromycin could reduce OR52D1 protein levels by causing the premature termination of mRNA translation, leading to the production of truncated, nonfunctional proteins and a decrease in full-length OR52D1 protein synthesis.

α-Amanitin

23109-05-9sc-202440
sc-202440A
1 mg
5 mg
$269.00
$1050.00
26
(2)

α-Amanitin may inhibit the expression of OR52D1 by binding strongly to RNA polymerase II, leading to a cessation of OR52D1 mRNA production due to the inhibition of mRNA elongation during transcription.

Cycloheximide

66-81-9sc-3508B
sc-3508
sc-3508A
100 mg
1 g
5 g
$41.00
$84.00
$275.00
127
(6)

Cycloheximide might suppress OR52D1 protein production by blocking the translocation step in protein synthesis, leading to an overall reduction in the translation of OR52D1 mRNA in the cytoplasm.